Evoke Pharma (EVOK)
(Delayed Data from NSDQ)
$4.24 USD
-0.12 (-2.75%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $4.24 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Evoke Pharma, Inc. [EVOK]
Reports for Purchase
Showing records 21 - 40 ( 79 total )
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Gimoti - Filing Accepted for Review; 2Q18 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Gimoti- New Drug Application Filed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
First Gender-Specific Patent Granted for Gimoti; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
License Agreement Amended; Cash Runway Into January 2019; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
4Q and FY2017 Results Reported; Looking Ahead to Gimoti NDA Submission; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
PDUFA Fee Small Business Waiver Approved; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Further Gender-Based Differences Unearthed; New Drug Application Postponed Slightly; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
3Q17 Financial Results Reported; Regulatory Filing for Gimoti Next; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Positive Pharmacokinetic Study Paves Pathway for NDA Filing Near-term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Gimoti Pharmacokinetic (PK) Study Complete; Looking Ahead to NDA Submission; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
2Q17 Financial Results Reported; Looking Ahead to PK Study Data and NDA Submission; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
1Q17 Financial Results Reported; PK Study up Next; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
1Q17 Financial Results Reported; PK Study up Next; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Multiple Recent Milestones Achieved; Late-Breaker at DDW; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Multiple Recent Milestones Achieved; Late-Breaker at DDW; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
FY2016 Results Reported; Preparing for NDA Filing; Reiterate Buy and Raising Price Target
Provider: Rodman & Renshaw, Co.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
FY2016 Results Reported; Preparing for NDA Filing; Reiterate Buy and Raising Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
We are dropping coverage of Evoke Pharma due to reallocation of resources.
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Supplemental Gimoti Phase 3 Data Provides Possible Path to Approval; Upgrading to Buy
Provider: Rodman & Renshaw, Co.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Supplemental Gimoti Phase 3 Data Provides Possible Path to Approval; Upgrading to Buy
Provider: H.C. Wainwright & Co., Inc.